

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

CHANGE OF JOINT COMPANY SECRETARY

The board of directors (the “**Board**”) of WuXi Biologics (Cayman) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. Yong Tong (“**Mr. Tong**”) has resigned as a joint company secretary of the Company (the “**Joint Company Secretary**”) with effect from November 20, 2018 due to internal re-designation of job functions. Mr. Tong confirms that there is no disagreement between himself and the Board and there are no other matters in relation to his resignation that need to be brought to the attention to the shareholders of the Company.

The Board further announces that Mr. Huang Yue (“**Mr. Huang**”) has been appointed as the Joint Company Secretary in replacement of Mr. Tong with effect from November 20, 2018. Ms. Cheng Pik Yuk (“**Ms. Cheng**”) will continue to act as the other Joint Company Secretary.

The biography of Mr. Huang is set out below:

Mr. Huang has joined the Group since February 2018 and worked as the Senior Director of the secretary office to the Board, mainly responsible for the company secretarial work of the Company. Mr. Huang has over 10 years of experience in the corporate legal field. Prior to joining the Group, Mr. Huang served different corporate legal roles, including legal manager of Far East Horizon Limited, a financial leasing company in the PRC, responsible for overseeing the mergers and acquisitions projects in the healthcare sector; an attorney of JunHe LLP, a reputable PRC law firm, responsible for advising corporate clients in mergers and acquisitions, general corporate and international trade projects; and an attorney in Huang Shan & Co., a law firm in the PRC, mainly responsible for representing clients in mergers and

acquisitions, general corporate and international trade projects. Mr. Huang graduated from Shanghai University of Finance and Economics with an LLB degree and a bachelor's degree in Management in July 2002. He then obtained an LLM degree from Stockholm University in Sweden in March 2007. Mr. Huang has also obtained the PRC Bar qualification in 2008.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Pursuant to Rule 8.17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”), a listed issuer must appoint a company secretary who meets the requirements under Rule 3.28 of the Listing Rules. Rule 3.28 of the Listing Rules provides that a listed issuer must appoint as its company secretary an individual who, in the opinion of the Stock Exchange, is capable of discharging the functions of company secretary of the listed issuer by virtue of his/her academic or professional qualifications or relevant experience.

As Mr. Huang does not hold the professional qualifications or the relevant experience required by Rule 3.28 of the Listing Rules, the Company has applied to the Stock Exchange for, and the Stock Exchange has granted the Company, a waiver (the “**Waiver**”) from strict compliance with the requirements of Rules 3.28 and 8.17 of the Listing Rules for a period of three years (the “**Waiver Period**”), commencing from November 20, 2018, being the date of appointment of Mr. Huang as a Joint Company Secretary, on the following conditions:

- (i) Mr. Huang will be assisted by Ms. Cheng, the other Joint Company Secretary, during the Waiver Period and the Waiver will be revoked immediately if and when Ms. Cheng ceases to provide assistance to Mr. Huang;
- (ii) the Company shall notify the Stock Exchange at the end of the Waiver Period for the Stock Exchange to re-visit the situation. The Stock Exchange expects that, after the end of the Waiver Period, the Company will be able to demonstrate that Mr. Huang can satisfy the requirements under Rules 3.28 and 8.17 of the Listing Rules after having the benefit of Ms. Cheng's assistance such that a further waiver will not be necessary; and
- (iii) the Company discloses the details of the Waiver, including its reasons therefor and the waiver conditions thereof, by way of announcement.

The Stock Exchange may withdraw or change the Waiver if the Company's situation changes.

The Board would like to take this opportunity to express its gratitude to Mr. Tong for his valuable contribution to the Company during his tenure of service as the Joint Company Secretary and extend its warm welcome to Mr. Huang for his new appointment.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, November 20, 2018

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Edward Hu, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Wo Felix Fong as independent non-executive Directors.

* *For identification purpose only*